Novo Nordisk's amycretin proves 13.1% weight loss potential in a 3-month Phase I trial; further research required for full assessment.
Novo Nordisk's experimental weight-loss pill, amycretin, has shown promising results in a Phase I trial, helping overweight and obese individuals lose up to 13.1% of their body weight in just three months. The drug works by mimicking hormones that regulate appetite and was found to be safe and tolerable, with mild-to-moderate side effects. Experts have noted the significant weight loss potential, indicating further studies are needed to fully assess its efficacy and safety.
September 10, 2024
42 Articles